MedPath

Phase 1/2 clinical trial of image-guided hypofractionated intensity-modulated radiotherapy/volumetric modulated arc therapy for localized low- or intermediate-risk prostate cancer

Phase 1
Conditions
Prostate cancer
Registration Number
JPRN-UMIN000010295
Lead Sponsor
Tohoku University
Brief Summary

A total of 12 patients were enrolled from March 2013 to April 2017 after institutional ethics committee approval. The study was terminated in November 2017 because the target number was not reached. No serious adverse events of Grade 3 or higher were observed in either the gastrointestinal tract or the urinary tract during the period. No biochemical recurrence was observed within the period.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Male
Target Recruitment
12
Inclusion Criteria

Not provided

Exclusion Criteria

1)Prior pelvic radiotherapy 2)Small cell carcinoma 3)cT3-4, exist of metastasis 4)Prior prostatectomy 5)Concurrent invasive cancers or collagen disease 6)PSA failure following hormonal therapy 7)If the attending physician judges the case inappropriate. 8)Gold allergy 9)Severe diabetes mellitus 10)Usage of anticoagulants/antiaggregant 11)Biochemical failure after hormonal therapy 12)Difficult to comply with dose constraints 13)IPSS>or=20

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
5-y biochemical relapse free survival
Secondary Outcome Measures
NameTimeMethod
5-y distant metastasis free survival 5-y cause-specific survival 5-y overall survival Toxicity (acute and late)
© Copyright 2025. All Rights Reserved by MedPath